United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - butorphanol tartrate (unii: 2l7i72ruhn) (butorphanol - unii:qv897jc36d) - butorphanol tartrate 1 mg in 1 ml - butorphanol tartrate injection is indicated: - as a preoperative or pre-anesthetic medication - as a supplement to balanced anesthesia - for the relief of pain during labor, and - for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve butorphanol tartrate injection for use in patients for whom alternative treatment options [e.g. non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia butorphanol tartrate injection is contraindicated in: - patients with significant respiratory depression [see warnings ] - patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - patients with known or suspected gastrointestinal

United States - English - NLM (National Library of Medicine)

hospira, inc. - butorphanol tartrate (unii: 2l7i72ruhn) (butorphanol - unii:qv897jc36d) - butorphanol tartrate 2 mg in 1 ml - butorphanol tartrate injection is indicated because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see warnings ], reserve butorphanol tartrate for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): butorphanol tartrate injection should not be used for an extended period of time unless the pain ‎remains severe enough to require an opioid analgesic and for which ‎alternative treatment options continue to be inadequate.‎ butorphanol tartrate injection is contraindicated in: butorphanol tartrate injection contains butorphanol, a schedule iv controlled substance. butorphanol tartrate injection contains butorphanol, a substance with high potential ‎for misuse and abuse, which can lead to the development of substance use ‎disorder, including addiction [see warnings ]. misuse is the intentional use, for therapeutic purposes, of a drug by an ‎individual in a way other than prescribed by a healthcare provider or for ‎whom it was not prescribed.‎ abuse is the intentional non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful ‎consequences, giving a higher priority to drug use than other activities ‎and obligations), and possible tolerance or physical dependence.‎ misuse and abuse of butorphanol tartrate injection increases risk of overdose, which ‎may lead to central nervous system and respiratory depression, ‎hypotension, seizures, and death. the risk is increased with concurrent ‎abuse of butorphanol tartrate injection with alcohol and other cns ‎depressants. abuse of and addiction to opioids in some individuals may ‎not be accompanied by concurrent tolerance and symptoms of physical ‎dependence. in addition, abuse of opioids can occur in the absence of ‎addiction.‎ all patients treated with opioids require careful and frequent reevaluation ‎for signs of misuse, abuse, and addiction, because use of opioid analgesic ‎products carries the risk of addiction even under appropriate medical use. ‎patients at high risk of butorphanol tartrate injection abuse include those with a history ‎of prolonged use of any opioid, including products containing butorphanol, those with a ‎history of drug or alcohol abuse, or those who use butorphanol tartrate injection in ‎combination with other abused drugs.‎ “drug-seeking” behavior is very common in persons with substance use disorders. drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). “doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control. butorphanol tartrate injection, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. abuse of butorphanol tartrate injection poses a risk of overdose and death. the risk is increased with concurrent use of butorphanol tartrate injection with alcohol and/or other cns depressants. parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and hiv. both tolerance and physical dependence can develop during use of opioid therapy. tolerance is a physiological state characterized by a reduced response to a drug ‎after repeated administration (i.e., a higher dose of a drug is required to ‎produce the same effect ‎that was once obtained at a lower dose).‎ physical dependence is a state that develops as a result of a physiological adaptation in ‎response to repeated drug use, manifested by withdrawal signs and ‎symptoms after abrupt discontinuation or a significant dose reduction of a ‎drug.‎ withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g.,pentazocine, butorphanol, nalbuphine), or partial agonists (e.g.,buprenorphine). physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use. butorphanol tartrate injection should not be abruptly discontinued in a physically-dependent patient‎ [see dosage and administration ]. if butorphanol tartrate is abruptly discontinued in a physically‑dependent patient, a withdrawal syndrome may occur, typically characterized by‎ restlessness, lacrimation, rhinorrhea, perspiration, chills, myalgia, and mydriasis. other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. infants born to mothers physical-dependent on opioids will also be physically-dependent and may exhibit respiratory difficulties and withdrawal signs [see precautions; pregnancy ].

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - terbinafine hydrochloride, quantity: 281.25 mg (equivalent: terbinafine, qty 250 mg) - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate - treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - butorphanol base as butorphanol tartrate - parenteral liquid/solution/suspension - butorphanol base as butorphanol tartrate alkaloid active 10.0 mg/ml - anaesthetics/analgesics - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - analgesic | sedative | antipyretic | colic | muscle relaxant | sedative | spasmolytic

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; maize starch; sodium starch glycollate type a; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid -

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - daclizumab -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - panobinostat lactate -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - panobinostat lactate -